Sinovac Biotech Stock Net Income
| SVA Stock | USD 6.47 0.00 0.00% |
By evaluating key metrics such as revenue growth, profitability, cash flow trends, and balance sheet strength, investors can better assess Sinovac Biotech's long-term financial health and intrinsic value.
| Last Reported | Projected for Next Year | ||
| Net Loss | -297.1 M | -282.3 M | |
| Net Income Applicable To Common Shares | 120 M | 126 M | |
| Net Loss | -297.1 M | -282.3 M | |
| Net Loss | (0.90) | (0.86) | |
| Net Income Per E B T | 0.59 | 0.49 |
Sinovac | Net Income | Build AI portfolio with Sinovac Stock |
Sinovac Biotech Company Net Income Analysis
Sinovac Biotech's Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Current Sinovac Biotech Net Income | (258.36 M) |
Most of Sinovac Biotech's fundamental indicators, such as Net Income, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Sinovac Biotech is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Sinovac Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Sinovac Biotech is extremely important. It helps to project a fair market value of Sinovac Stock properly, considering its historical fundamentals such as Net Income. Since Sinovac Biotech's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Sinovac Biotech's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Sinovac Biotech's interrelated accounts and indicators.
Click cells to compare fundamentals
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Sinovac Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Sinovac Biotech reported net income of (258.36 Million). This is 175.7% lower than that of the Biotechnology sector and significantly lower than that of the Health Care industry. The net income for all United States stocks is 145.25% higher than that of the company.
Sinovac Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Sinovac Biotech's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Sinovac Biotech could also be used in its relative valuation, which is a method of valuing Sinovac Biotech by comparing valuation metrics of similar companies.Sinovac Biotech is currently under evaluation in net income category among its peers.
Sinovac Biotech Current Valuation Drivers
We derive many important indicators used in calculating different scores of Sinovac Biotech from analyzing Sinovac Biotech's financial statements. These drivers represent accounts that assess Sinovac Biotech's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Sinovac Biotech's important valuation drivers and their relationship over time.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Market Cap | 639.9M | 642.5M | 643.8M | 644.5M | 580.0M | 609.0M | |
| Enterprise Value | (264.8M) | (10.8B) | (3.6B) | (326.7M) | (375.7M) | (394.5M) |
Sinovac Biotech ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Sinovac Biotech's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Sinovac Biotech's managers, analysts, and investors.Environmental | Governance | Social |
Sinovac Biotech Institutional Holders
Institutional Holdings refers to the ownership stake in Sinovac Biotech that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Sinovac Biotech's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Sinovac Biotech's value.| Shares | Morgan Stanley - Brokerage Accounts | 2025-06-30 | 8.3 K | Bank Of America Corp | 2025-06-30 | 5.9 K | Ubs Group Ag | 2025-06-30 | 2.2 K | Advisor Group Holdings, Inc. | 2025-06-30 | 2.1 K | Atlantic Edge Private Wealth Management Llc | 2025-06-30 | 1000 | Hartland & Co | 2025-06-30 | 500 | Royal Bank Of Canada | 2025-06-30 | 425 | Tower Research Capital Llc | 2025-06-30 | 424 | Ifp Advisors, Llc | 2025-06-30 | 200 | Vivo Capital, Llc | 2025-06-30 | 5.9 M | Orbimed Advisors, Llc | 2025-06-30 | 2.7 M |
Sinovac Fundamentals
| Return On Equity | 0.25 | ||||
| Return On Asset | 0.11 | ||||
| Profit Margin | 0.22 % | ||||
| Operating Margin | 0.42 % | ||||
| Current Valuation | 297.09 M | ||||
| Shares Outstanding | 99.29 M | ||||
| Shares Owned By Insiders | 51.42 % | ||||
| Shares Owned By Institutions | 32.02 % | ||||
| Number Of Shares Shorted | 82.76 K | ||||
| Price To Earning | 48.65 X | ||||
| Price To Book | 1.82 X | ||||
| Price To Sales | 1.83 X | ||||
| Revenue | 448.27 M | ||||
| Gross Profit | 443.44 M | ||||
| EBITDA | (6.03 M) | ||||
| Net Income | (258.36 M) | ||||
| Cash And Equivalents | 176.72 M | ||||
| Cash Per Share | 1.79 X | ||||
| Total Debt | 298.98 M | ||||
| Debt To Equity | 0.28 % | ||||
| Current Ratio | 2.98 X | ||||
| Book Value Per Share | 7.52 X | ||||
| Cash Flow From Operations | 106.02 M | ||||
| Earnings Per Share | 0.97 X | ||||
| Target Price | 3.52 | ||||
| Number Of Employees | 1.96 K | ||||
| Beta | 0.0649 | ||||
| Market Capitalization | 642.44 M | ||||
| Total Asset | 13.66 B | ||||
| Retained Earnings | 7.12 B | ||||
| Working Capital | 10.68 B | ||||
| Current Asset | 128.52 M | ||||
| Current Liabilities | 58 M | ||||
| Annual Yield | 8.50 % | ||||
| Net Asset | 13.66 B |
About Sinovac Biotech Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Sinovac Biotech's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Sinovac Biotech using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Sinovac Biotech based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Sinovac Biotech offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Sinovac Biotech's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Sinovac Biotech Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Sinovac Biotech Stock:Check out Sinovac Biotech Piotroski F Score and Sinovac Biotech Altman Z Score analysis. For information on how to trade Sinovac Stock refer to our How to Trade Sinovac Stock guide.You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sinovac Biotech. If investors know Sinovac will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sinovac Biotech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 3.548 | Earnings Share 0.971 | Revenue Per Share | Quarterly Revenue Growth 3.037 | Return On Assets |
The market value of Sinovac Biotech is measured differently than its book value, which is the value of Sinovac that is recorded on the company's balance sheet. Investors also form their own opinion of Sinovac Biotech's value that differs from its market value or its book value, called intrinsic value, which is Sinovac Biotech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sinovac Biotech's market value can be influenced by many factors that don't directly affect Sinovac Biotech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Sinovac Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine if Sinovac Biotech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sinovac Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.